Alexander L Rakhmilevich Selected Research

Lipopolysaccharides

10/2012	Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.
6/2006	Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexander L Rakhmilevich Research Topics

Disease

45	Neoplasms (Cancer) 04/2024 - 09/2002
11	Neuroblastoma 04/2024 - 01/2004
9	Melanoma (Melanoma, Malignant) 12/2023 - 01/2011
6	Experimental Melanoma 01/2021 - 05/2005
4	Necrosis 05/2011 - 06/2006
3	Breast Neoplasms (Breast Cancer) 03/2024 - 08/2004
3	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2004
2	Lymphoma (Lymphomas) 01/2021 - 02/2009
2	Adenocarcinoma 08/2004 - 09/2002
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Colonic Neoplasms (Colon Cancer) 08/2009
1	Sarcoma (Soft Tissue Sarcoma) 08/2008
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2007
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 06/2006
1	Lymphadenopathy 09/2002
1	Splenomegaly 09/2002
1	Renal Cell Carcinoma (Grawitz Tumor) 09/2002

Drug/Important Bio-Agent (IBA)

13	Interleukin-2 (IL2)IBA 04/2024 - 01/2004
9	Monoclonal AntibodiesIBA 04/2024 - 08/2004
9	lorukafusp alfaIBA 04/2024 - 01/2004
6	VaccinesIBA 07/2023 - 01/2021
6	CytokinesIBA 01/2021 - 06/2006
5	OligodeoxyribonucleotidesIBA 07/2023 - 03/2007
5	Interleukin-12 (IL 12)IBA 09/2022 - 09/2002
3	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2021
3	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 12/2008
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2012 - 06/2006
3	DNA (Deoxyribonucleic Acid)IBA 11/2011 - 09/2002
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2007 - 01/2006
2	AntibodiesIBA 10/2020 - 01/2016
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2018
2	AntigensIBA 04/2013 - 01/2011
2	LipopolysaccharidesIBA 10/2012 - 06/2006
2	Interferon-gamma (Interferon, gamma)IBA 10/2012 - 01/2004
2	ResveratrolIBA 11/2011 - 05/2011
1	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2024
1	salicylhydroxamic acid (SHAM)IBA 03/2024
1	liposomal doxorubicin (Doxil)FDA Link 03/2024
1	CollagenIBA 03/2024
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023
1	Immunologic Factors (Immunomodulators)IBA 01/2023
1	carboxyaminoimidazole ribotide (CAIR)IBA 01/2022
1	bempegaldesleukinIBA 01/2021
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 10/2020
1	Neoplasm AntibodiesIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Therapeutic UsesIBA 01/2018
1	ChemokinesIBA 08/2015
1	Gemcitabine FDA Link 12/2013
1	Fluorouracil (Carac)FDA LinkGeneric 12/2013
1	Recombinant ProteinsIBA 08/2013
1	EpitopesIBA 01/2011
1	tucotuzumab celmoleukinIBA 08/2009
1	TNF-Related Apoptosis-Inducing LigandIBA 03/2007
1	Interleukin-1alpha (Interleukin 1 alpha)IBA 03/2007
1	Fas Ligand Protein (Fas Ligand)IBA 03/2007
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2004
1	Histocompatibility Antigens Class IIBA 01/2004
1	Complementary DNA (cDNA)IBA 09/2002
1	LipidsIBA 09/2002

Therapy/Procedure

22	Immunotherapy 04/2024 - 09/2002
12	Therapeutics 04/2024 - 01/2004
9	Radiotherapy 04/2024 - 01/2016
5	Ligation 08/2012 - 05/2005
4	Drug Therapy (Chemotherapy) 12/2013 - 06/2009
2	Intraperitoneal Injections 01/2013 - 05/2005
1	Injections 01/2023
1	Neoadjuvant Therapy 01/2022
1	Intravenous Injections 10/2020
1	Radiofrequency Ablation 08/2009
1	Aftercare (After-Treatment) 08/2009
1	Transplantation 06/2009